|Idealized depiction of this compound (top), and a picture of a sample (bottom).|
|Systematic (IUPAC) name|
|Trade names||Nipride, Nitropress|
|Licence data||US FDA:|
|Pregnancy cat.||C (AU) C (US)|
|Legal status||Prescription Only (S4) (AU) ℞-only (CA) POM (UK) ℞-only (US)|
|Metabolism||By haemoglobin being converted to cyanmethaemoglobin and cyanide ions|
|Half-life||<2 minutes (3 days for thiocyanate metabolite)|
|Excretion||Renal (100%; as thiocyanate)|
|Solubility in water||100 mg/mL (20 °C)|
Sodium nitroprusside is an inorganic compound with the formula Na2[Fe(CN)5NO], usually encountered as the dihydrate, Na2[Fe(CN)5NO]·2H2O. This red-colored sodium salt dissolves in water ethanol to give solutions containing the free complex dianion [Fe(CN)5NO]2−.
This compound is used as a drug. In this role it is abbreviated SNP, and it has tradenames like Nitropress. It acts as a drug by releasing nitric oxide; it belongs to the class of NO-releasing drugs as a result. This drug is used as a vasodilator to reduce blood pressure. Sodium nitroprusside is also used as an analytical reagent for the detection of methyl ketones, and for the detection of amines that are often found in illicit drugs.
Sodium nitroprusside is primarily used as a vasodilator. It was first used in human medicine in 1928. By 1955, data on its safety during short-term use in patients with severe hypertension had become available. Despite this, due to difficulties in its chemical preparation, it was not until 1974 that it was finally approved by the US FDA for the treatment of severe hypertension. By 1993 its popularity had grown such that total sales in the US had totalled $2 million USD.
Sodium nitroprusside has potent vasodilating effects in arterioles and venules (arterioles more than venuols, but this selectivity is much less marked than that of nitroglycerin) as a result of its breakdown to nitric oxide (NO). It is intravenously infused in cases of acute hypertensive crises. Its therapeutic effects are usually seen within a few minutes.
Nitric oxide reduces both total peripheral resistance as well as venous return, thus decreasing both preload and afterload. For this reason, it can be used in severe congestive heart failure where this combination of effects can act to increase cardiac output. In situations where cardiac output is normal, the effect is to reduce blood pressure. It is sometimes also used to induce hypotension (in order to reduce bleeding) for surgical procedures (for which it is also FDA, TGA and MHRA labelled).
This compound has also been successfully used as a treatment for: aortic valve stenosis, erythromelalgia, oesophageal varices, severe pyrexia (fever), lactic acidosis, myocardial infarction, neuroleptic malignant syndrome, pulmonary hypertension, respiratory distress syndrome in the newborn, shock, cerebral vasospasm, ergot toxicity, ventricular septal defects.
- Chest discomfort
- Paraesthesial warmth
- Abdominal pain
- Orthostatic hypotension
- ECG changes
- Skin irritation
- Injection site erythema
- Injection site streaking
- Reduced platelet aggregation
- Increased intracranial pressure
- Metabolic acidosis
- Cyanide poisoning
- Thiocyanate toxicity
Sodium nitroprusside should not be used for compensatory hypertension (e.g. due to an anteriovenous stunt or coarctation of the aorta). It should not be used in patients with inadequate cerebral circulation or in patients that are near death. It should not be used in patients with vitamin B12 deficiency, anaemia, severe renal disease or hypovolaemia. Patients with conditions that are associated with a higher cyanide/thiocyanate ratio (e.g. congenital (Leber's) optic atrophy, tobacco amblyopia) should only be treated with sodium nitroprusside with great caution. Its use in patients with acute congestive heart failure that is associated with reduced peripheral resistance is also not recommended. Its use in hepatically impaired individuals is also not recommended, as is its use in cases of pre-existing hypothyroidism.
Its use in pregnant women is advised against, although the available evidence suggests it may be safe, provided maternal pH and cyanide levels are closely monitored. There is evidence to suggest that sodium nitroprusside use in critically ill children may be safe, even without monitouring of cyanide level.
- Discontinuing sodium nitroprusside administration
- Buffering the cyanide by using sodium nitrite to convert haemoglobin to methaemoglobin as much as the patient can safely tolerate
- Infusing sodium thiosulfate to convert the cyanide to thiocyanate.
The cyanide can be detoxified by reaction with a sulfur-donor such as thiosulfate, catalysed by the enzyme rhodanese. In the absence of sufficient thiosulfate, cyanide ions can quickly reach toxic levels.
|Species||LD50 (mg/kg) for oral administration||LD50 (mg/kg) for IV administration||LD50 (mg/kg) for skin administration|
Mechanism of action
Sodium nitroprusside breaks down in circulation to release nitric oxide (NO). It does this by binding to oxyhaemoglobin to release cyanide, methaemoglobin and nitric oxide. NO activates guanylate cyclase in vascular smooth muscle and increases intracellular production of cGMP. cGMP activates protein kinase G which activates phosphatases which inactivate myosin light chains. Myosin light chains are involved in muscle contraction. The end result is vascular smooth muscle relaxation, which allow vessels to dilate. This mechanism is similar to that of phosphodiesterase 5 (PDE5) inhibitors such as sildenafil (Viagra) and tadalafil (Cialis), which elevate cGMP concentration by inhibiting its degradation by PDE5.
A role for NO in various common psychiatric disorders including schizophrenia, bipolar disorder and major depressive disorder has been proposed and supported by several clinical findings. These findings may also implicate the potential of drugs that alter NO signalling such as SNP in their treatment. Such a role is also supported by the findings of the recent SNP clinical trial and other clinical trials that have demonstrated the efficacy of minocycline (a nitric oxide synthase inhibitor) in treating the negative and cognitive symptoms of schizophrenia.
Structure and properties
Nitroprusside is a complex anion that features an octahedral iron(II) centre surrounded by five tightly bound cyanide ligands and one linear nitric oxideligand (Fe-N-O angle = 176.2 °). The anion possesses idealized C4vsymmetry.
Nitric oxide is a non-innocent ligand. Due to the linear Fe-N-O angle, the relatively short N-O distance of 113 pm and the relatively high stretching frequency of 1947 cm−1, the complex is formulated as containing an NO+ ligand. Consequently, iron is assigned an oxidation state of 2+. The iron center has a diamagnetic low-spin d6 electron configuration, although a paramagnetic long-lived metastable state has been observed by EPR spectroscopy.
The chemical reactions of sodium nitroprusside are mainly associated with the NO ligand. For example, addition of S2- ion to [Fe(CN)5(NO)]2- produces the red [Fe(CN)5(NOS)]4- ion, which is the basis for a sensitive test for S2- ions. An analogous reaction also exists with OH- ions, giving [Fe(CN)5(NO2)]4-. Roussin's red salt (K2[Fe2S2(NO)4]) and Roussin's black salt (NaFe4S3(NO)7) are related iron nitrosyl complexes. The former was first prepared by treating nitroprusside with sulfur.
This compound decomposes to sodium ferrous ferrocyanide, sodium ferrocyanide, nitric oxide, and cyanogen at about 450 °C. It decomposes in aqueous acid to liberate hydrocyanic acid (HCN). Shielded from light, the concentrated solution is stable for more than two years at room temperature. It breaks down rapidly upon exposure to light, although the details are poorly understood. It degrades when heated (e.g. by sterilization in an autoclave), but addition of citric acid is helpful.
- K4[Fe(CN)6] + 6 HNO3 → H2[Fe(CN)5(NO)] + CO2 + NH4NO3 + 4 KNO3
- H2[Fe(CN)5NO] + Na2CO3 → Na2[Fe(CN)5(NO)] + CO2 + H2O
- [Fe(CN)6]4- + H2O + NO2- → [Fe(CN)5(NO)]2- + CN- + 2 OH-
Sodium nitroprusside was found by Legal to give a reaction with acetone or creatine under basic conditions in 1882. Rothera refined this method by the use of ammonia in place of sodium or potassium hydroxide. The reaction was now specific for methyl ketones. Addition of ammonium salts (e.g. ammonium sulfate) improved the sensitivity of the test too. This test is known as Rothera's test.
In Rothera's test, methyl ketones (CH3C(=O)-) under alkaline conditions to give bright red coloration (see also iodoform test). Rothera's test was initially applied to detecting ketonuria (a symptom of diabetes) in urine samples. This reaction is now exploited in the form of urine test strips (e.g. "Ketostix").
Sodium nitroprusside is used in a separate urinalysis test known as the cyanide nitroprusside test or Brand's test. In this test sodium cyanide is added first to urine and let stand for approximately 10 minutes. In this time disulfide bonds will be broken by the released cyanide. The destruction of disulfide bonds liberates cysteine from cystine and homocysteine from homocystine. Next sodium nitroprusside is added to the solution and it reacts with the newly freed sulfhydryl groups. The test will turn a red/purple colour if the test is positive indicating that there was significant amounts of amino acid in the urine (aminoaciduria). Cysteine, cystine, homocysteine and homocystine all react when present in the urine when this test is performed. This test can indicate inborn errors of amino acid transporters such as cystinuria, which results from pathology in the transport of dibasic amino acids.
Sodium nitroprusside is also able to detect amines. This compound is thus used as a stain to visualize amines in thin layer chromatography. Sodium nitroprusside is similarly used as a presumptive test for the presence of alkaloids (amine-containing natural products) that are common in illicit substances. The test, called Simon's test, is performed by adding 1 volume of a solution of sodium nitroprusside and acetaldehyde in deionized water to a suspected drug, followed by the addition of 2 volumes of an aqueous sodium carbonate solution. The test turns blue for some secondary amines. The most common secondary amines encountered in forensic chemistry include 3,4-methylenedioxymethamphetamine (MDMA, the main component in Ecstasy) and phenethylamines such as methamphetamine. Sodium nitropruside is also useful in the identification the mercaptans (thiol groups).
Sodium nitroprusside is often used as a reference compound for the calibration of Mössbauer spectrometers. Sodium nitroprusside crystals are also of interest for optical storage. For this application, sodium nitroprusside can be reversibly promoted to a metastable excited state by blue-green light, and de-excited by heat or red light.
In physiology research, sodium nitroprusside is frequently used to test endothelium-independent vasodilation. Iontophoresis, for example, allows local administration of the drug, preventing the systemic effects listed above but still inducing local microvascular vasodilation. Sodium nitroprusside is also used in microbiology, where it has been linked with the dispersal of Pseudomonas aeruginosa biofilms by acting as a nitric oxide donor.
- Brunton, L; Chabner, B; Knollman, B (2010). Goodman and Gilman's The Pharmacological Basis of Therapeutics (in English) (12th ed.). New York: McGraw-Hill Professional. ISBN 978-0-07-162442-8.
- A. R. Butler, I. L. Megson (2002). "Non-Heme Iron Nitrosyls in Biology". Chemical Reviews 102 (4): 1155–1165. doi:10.1021/cr000076d.
- Friederich, JA; Butterworth, JF 4th (July 1995). "Sodium Nitroprusside: Twenty Years and Counting". Anesthesia and Analgesia 81 (1): 152–162. PMID 7598246.
- "NITROPRESS (sodium nitroprusside) injection, solution, concentrate [Hospira, Inc.]". DailyMed. Hospira, Inc. January 2011. Retrieved 20 November 2013.
- "DBL® SODIUM NITROPRUSSIDE FOR INJECTION BP" (PDF). TGA eBusiness Services. Hospira Australia Pty Ltd. 22 April 2010. Retrieved 20 November 2013.
- "nitroprusside sodium (Rx) - Nipride, Nitropress, more..". Medscape Reference. WebMD. Retrieved 20 November 2013.
- Joint Formulary Committee (2013). British National Formulary (BNF) (65 ed.). London, UK: Pharmaceutical Press. ISBN 978-0-85711-084-8.
- Rossi, S, ed. (2013). Australian Medicines Handbook (2013 ed.). Adelaide: The Australian Medicines Handbook Unit Trust. ISBN 978-0-9805790-9-3.
- Ikram, H; Low, CJ; Crozier, IG; Shirlaw, T (February 1992). "Hemodynamic effects of nitroprusside on valvular aortic stenosis". The American Journal of Cardiology 69 (4): 361–366. doi:10.1016/0002-9149(92)90234-P. PMID 1734649.
- Ozsoylu, S; Coşkun, T (January 1984). "Sodium nitroprusside treatment in erythromelalgia". European Journal of Pediatrics 141 (3): 185–187. PMID 6698066.
- Sirinek, KR; Adcock, DK; Levine, BA (January 1989). "Simultaneous infusion of nitroglycerin and nitroprusside to offset adverse effects of vasopressin during portosystemic shunting". American Journal of Surgery 157 (1): 33–37. doi:10.1016/0002-9610(89)90416-9. PMID 2491934.
- Katlic, MR; Ramos, LG; Zinner, MJ (August 1978). "Sodium nitroprusside in the treatment of extreme pyrexia (letter)". The New England Journal of Medicine 299 (3): 154.
- Taradash, MR; Jacobson, LB (September 1975). "Vasodilator therapy of idiopathic lactic acidosis". The New England Journal of Medicine 293 (10): 468–471. doi:10.1056/NEJM197509042931002. PMID 239336.
- Yusuf, S; Collins, R; MacMahon, S; Peto, R (May 1988). "Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview of the randomised trials". Lancet 1 (8594). doi:10.1016/S0140-6736(88)91906-X. PMID 2896919.
- Blue, MG; Schneider, SM; Noro, S; Fraley, DS (January 1986). "Successful treatment of neuroleptic malignant syndrome with sodium nitroprusside". Annals of Internal Medicine 104 (1): 56–57. doi:10.7326/0003-4819-104-1-56. PMID 3940506.
- Costard-Jäckle, A; Fowler, MB (January 1992). "Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibility of pulmonary hypertension with nitroprusside is useful in defining a high risk group". Journal of the American College of Cardiology 19 (1): 48–54. doi:10.1016/0735-1097(92)90050-W. PMID 1729345.
- Knapp, E; Gmeiner, R (February 1977). "Reduction of pulmonary hypertension by nitroprusside". International Journal of Clinical Pharmacology and Biopharmacy 15 (2): 75–80. PMID 885667.
- Freitas, AF Jr; Bacal, F; Oliveira Júnior Jde, L; Fiorelli, AI; Santos, RH; Moreira, LF; Silva, CP; Mangini, S; Tsutsui, JM; Bocchi, EA (September 2012). "Sildenafil vs. sodium before nitroprusside for the pulmonary hypertension reversibility test before cardiac transplantation". Arquivos Brasileiros de Cardiologia 99 (3). doi:10.1590/S0066-782X2012005000076. PMID 22898992.
- Palhares, DB; Figueiredo, CS; Moura, AJ (January 1998). "Endotracheal inhalatory sodium nitroprusside in severely hypoxic newborns". Journal of Perinatal Medicine 26 (3): 219–224. doi:10.1515/jpme.19220.127.116.11. PMID 9773383.
- Benitz, WE; Malachowski, N; Cohen, RS; Stevenson, DK; Ariagno, RL; Sunshine, P (January 1985). "Use of sodium nitroprusside in neonates: efficacy and safety". The Journal of Pediatrics 106 (1): 102–110. doi:10.1016/S0022-3476(85)80477-7. PMID 3917495.
- Levy, WJ; Bay, JW; Sawhny, B; Tank, T (May 1982). "Aminophylline plus nitroprusside and dopamine for treatment of cerebral vasospasm". Journal of Neurosurgery 56 (5): 646–649. PMID 7069476.
- Thomas, JE; Rosenwasser, RH (January 1999). "Reversal of severe cerebral vasospasm in three patients after aneurysmal subarachnoid hemorrhage: initial observations regarding the use of intraventricular sodium nitroprusside in humans". Neurosurgery 44 (1): 48–57. PMID 9894963.
- Dierckx, RA; Peters, O; Ebinger, G; Six, R; Corne, L (February 1986). "Intraarterial sodium nitroprusside infusion in the treatment of severe ergotism". Clinical Neuropharmacology 9 (6): 542–548. doi:10.1097/00002826-198612000-00005. PMID 3802106.
- Carliner, N; Denune, DP; Finch, CS Jr; Goldberg, LI (January 1974). "Sodium nitroprusside treatment of ergotamine-induced peripheral ischemia". Journal of the American Medical Association 227 (3): 308–309. doi:10.1001/jama.1974.03230160036008. PMID 4859658.
- Lewis, PJ; Noseworthy, TW; Fitzgerald, AA; Andrews, GC; Geeraert, AJ (February 1986). "Rapid reversal of ergotamine-induced vasospasm". The Canadian Journal of Neurological Sciences 13 (1): 72–74. PMID 3955457.
- Merhoff, GC; Porter, JM (November 1974). "Ergot intoxication: historical review and description of unusual clinical manifestations". Annals of Surgery 180 (5): 773–779. PMC 1343691. PMID 4371616.
- Kunathai, S; Ayuthya, PS (Winter 1989). "Hemodynamic effects of sodium nitroprusside in infants and children with large ventricular septal defect". Pediatric Cardiology 10 (1): 59. PMID 2704657.
- Sass, N; Itamoto, CH; Silva, MP; Torloni, MR; Atallah, AN (March 2007). "Does sodium nitroprusside kill babies? A systematic review". Sao Paulo Medical Journal 125 (2): 108–111. doi:10.1590/S1516-31802007000200008. PMID 17625709.
- Thomas, C; Svehla, L; Moffett, BS (September 2009). "Sodium nitroprusside induced cyanide toxicity in pediatric patients". Expert Opinion on Drug Safety 8 (5): 599–602. doi:10.1517/14740330903081717. PMID 19645589.
- Rindone, JP; Sloane, EP (April 1992). "Cyanide toxicity from sodium nitroprusside: Risks and management". Annals of Pharmacotherapy 26 (4): 515–519. PMID 1533553.
- "Nitropress (Nitroprusside Sodium) Drug Information: Clinical Pharmacology - Prescribing Information at RxList". RxList. RxList Inc. 4 July 2009. Retrieved 21 November 2013.
- "Material Safety Data Sheet Sodium nitroprusside, ACS" (PDF). Qorpak. Berlin Packaging. 1 August 2006. Retrieved 21 November 2013.
- "Cyclic Guanosine Monophosphate as a Mediator of Vasodilation" (PDF). The Journal of Clinical Investigation 78 (1): 1–5. July 1986. doi:10.1172/JCI112536. PMC 329522. PMID 2873150.
- Kukreja, RC; Salloum, FN; Das, A (May 2012). "Cyclic Guanosine Monophosphate Signaling and Phosphodiesterase-5 Inhibitors in Cardioprotection" (PDF). Journal of the American College of Cardiology 59 (22): 1921–1927. doi:10.1016/j.jacc.2011.09.086. PMID 22624832.
- Bernstein, HG; Bogerts, B; Keilhoff, G. "The many faces of nitric oxide in schizophrenia. A review". Schizophrenia Research 78 (1): 69–86. doi:10.1016/j.schres.2005.05.019. PMID 16005189.
- Silberberg, G; Ben-Shachar, D; Navon, R (October 2010). "Genetic analysis of nitric oxide synthase 1 variants in schizophrenia and bipolar disorder". American Journal of Medical Genetics Part B: Neuropsychiatric Genetics 153B (7): 1318–1328. doi:10.1002/ajmg.b.31112. PMID 20645313.
- Bernstein, HG; Keilhoff, G; Steiner, J; Dobrowolny, H; Bogerts, B (November 2011). "Nitric oxide and schizophrenia: present knowledge and emerging concepts of therapy". CNS & Neurological Disorders - Drug Targets 10 (7): 792–807. doi:10.2174/187152711798072392. PMID 21999729.
- Coyle, JT (July 2013). "Nitric Oxide and Symptom Reduction in Schizophrenia". JAMA Psychiatry 70 (7): 664–665. doi:10.1001/jamapsychiatry.2013.210. PMID 23699799.
- Yanik, M; Vural, H; Tutkun, H; Zoroğlu, SS; Savaş, HA; Herken, H; Koçyiğit, A; Keleş, H; Akyol, O (February 2004). "The role of the arginine-nitric oxide pathway in the pathogenesis of bipolar affective disorder". European Archives of Psychiatry and Clinical Neuroscience 254 (1): 43–47. doi:10.1007/s00406-004-0453-x. PMID 14991378.
- Fontoura, PC; Pinto, VL; Matsuura, C; Resende Ade, C; de Bem, GF; Ferraz, MR; Cheniaux, E; Brunini, TM; Mendes-Ribeiro, AC (October 2012). "Defective Nitric Oxide–Cyclic Guanosine Monophosphate Signaling in Patients With Bipolar Disorder: A Potential Role for Platelet Dysfunction". Psychosomatic Medicine 74 (8): 873–877. doi:10.1097/PSY.0b013e3182689460. PMID 23023680.
- Bielau, H; Brisch, R; Bernard-Mittelstaedt, J; Dobrowolny, H; Gos, T; Baumann, B; Mawrin, C; Bernstein, HG; Bogerts, B; Steiner, J (June 2012). "Immunohistochemical evidence for impaired nitric oxide signaling of the locus coeruleus in bipolar disorder". Brain Research 1459: 91–99. doi:10.1016/j.brainres.2012.04.022. PMID 22560594.
- Gałecki, P; Maes, M; Florkowski, A; Lewiński, A; Gałecka, E; Bieńkiewicz, M; Szemraj, J (March 2011). "Association between inducible and neuronal nitric oxide synthase polymorphisms and recurrent depressive disorder". Journal of Affective Disorders 129 (1-3). doi:10.1016/j.jad.2010.09.005. PMID 20888049.
- Dhir, A; Kulkarni, SK (April 2011). "Nitric oxide and major depression". Nitric Oxide 24 (3): 125–131. doi:10.1016/j.niox.2011.02.002. PMID 21335097.
- Savaş, HA; Herken, H; Yürekli, M; Uz, E; Tutkun, H; Zoroğlu, SS; Ozen, ME; Cengiz, B; Akyol, O (2002). "Possible role of nitric oxide and adrenomedullin in bipolar affective disorder". Neuropsychobiology 45 (2): 57–61. doi:10.1159/000048677. PMID 11893860.
- Hallak, Jaime E. C.; Maia-de-Oliveira, J. P., Abrao, J., Evora, P. R., Zuardi, A. W., Crippa, J. A., Belmonte-de-Abreu, P., Baker, G. B., Dursun, S.M. (8 May 2013). "Rapid improvement of acute schizophrenia symptoms after intravenous sodium nitroprusside: A randomized, double-blind, placebo-controlled trial". The Journal of the American Medical Association 70 (7): E3–E5. doi:10.1001/jamapsychiatry.2013.1292. PMID 23699763. Retrieved 11 March 2014.
- Miyaoka, T (November 2012). "Minocycline for Schizophrenia: A critical review". Open Journal of Psychiatry 2 (4A): 399–406. doi:10.4236/ojpsych.2012.224056.
- Catherine E. Housecroft; Alan G. Sharpe (2008). "Chapter 22: d-Block metal chemistry: the first row metals". Inorganic Chemistry, 3rd Edition. Pearson. p. 721. ISBN 978-0-13-175553-6.
- Jadwiga Tritt-Goc; Narcyz Piślewski; Stanisław K. Hoffmann (1997). "EPR evidence of the paramagnetism of a long-living metastable excited state of a sodium nitroprusside single crystal". Chemical Physics Letters 268 (5–6): 471–474. doi:10.1016/S0009-2614(97)00217-0.
- Coppens, P.; Novozhilova, I.; Kovalevsky, A. (2002). "Photoinduced Linkage Isomers of Transition-Metal Nitrosyl Compounds and Related Complexes". Chem. Rev. 102 (4): 861–883. doi:10.1021/cr000031c.
- Hans Reihlen, Adolf v. Friedolsheim (1927). "Über komplexe Stickoxydverbindungen und das sogenannte einwertige Eisen". Justus Liebigs Annalen der Chemie 457: 71. doi:10.1002/jlac.19274570103.
- J. J. Spijkerman; D. K. Snediker; F. C. Ruegg; J. R. Devoe. NBS Misc. Publ. 260-13: Mossbauer Spectroscopy Standard for the Chemical Shift of Iron Compounds. National Bureau of Standards.
- O. R. Leeuwenkamp; W. P. van Bennekom; E. J. van der Mark; A. Bult (1984). "Nitroprusside, antihypertensive drug and analytical reagent". Pharmaceutisch Weekblad 6 (4): 129–140. doi:10.1007/BF01954040.
- "Sodium Nitrosyl Cyanoferrate" in Handbook of Preparative Inorganic Chemistry, 2nd Ed. Edited by G. Brauer, Academic Press, 1963, NY. Vol. 1. p. 1768.
- A. C. H. Rothera (1908). "Note on the sodium nitro-prusside reaction for acetone". J. Physiol. 37 (5-6): 491–494. PMC 1533603.
- Comstock JP; Garber AJ. (1990). "Chapter 140. Ketonuria" (NCBI Bookshelf). In Walker HK; Hall WD; Hurst JW. Clinical Methods: The History, Physical, and Laboratory Examinations (3rd edition ed.). Boston: Butterworths.
- Finocchiaro R; D'Eufemia P; Celli M; Zaccagnini M; Viozzi L; Troiani P; Mannarino O; Giardini O. (1998). "Usefulness of cyanide-nitroprusside test in detecting incomplete recessive heterozygotes for cystinuria: a standardized dilution procedure". Urol Res. 26 (6): 401–5. doi:10.1007/s002400050076. PMID 9879820.
- "TLC Visualization Reagents". École Polytechnique Fédérale de Lausanne. Retrieved 2013-11-21.
- Carol L. O’Neala, Dennis J. Croucha, Alim A. Fatahb (2000). "Validation of twelve chemical spot tests for the detection of drugs of abuse". Forensic Science International 109: 189–201. doi:10.1016/S0379-0738(99)00235-2. PMID 10725655.
- Th. Woike; W. Krasser; P. S. Bechthold; S. Haussühl (1984). "Extremely Long-Living Metastable State of Na2[Fe(CN)5NO]·2H2O Single Crystals: Optical". 53: 1767–1770. doi:10.1103/PhysRevLett.53.1767.
- Barraud, N; Hassett, DJ; Hwang, SH; Rice, SA; Kjelleberg, S; Webb, JS (2006). "Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa". Journal of bacteriology 188 (21): 7344–53. doi:10.1128/JB.00779-06. PMC 1636254. PMID 17050922.